Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupCD30+ICD10C82.-C82.7C82.9C83.3C84.4C84.5C84.6C84.7C85.2C86.1C86.2C86.5C91.5-C94.7-MeSHEnteropathy-Associated T-Cell LymphomaLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralSequenceCHOP 21 (CYCL750/DOXO50/VNCR2/PRED40), EATL, part A (PID1650) -|- IVE/MTX (EPIR50/ETOP200/IFOS3/MTRX1500), part B (PID1651)STUDY - levelChemotherapyChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEpirubicinEtoposideGemcitabineIfosfamideMethotrexateNivolumabOxaliplatinPrednisoloneVincristineChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEpirubicinEtoposideGemcitabineIfosfamideMethotrexateNivolumabOxaliplatinPrednisoloneVincristineChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEpirubicinEtoposideGemcitabineIfosfamideMethotrexateNivolumabOxaliplatinPrednisoloneVincristineChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEpirubicinEtoposideGemcitabineIfosfamideMethotrexateNivolumabOxaliplatinPrednisoloneVincristineNo. Substances1234 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%Folinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%Folinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%Folinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%Folinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%PegfilgrastimPotassium chlorideSodium BicarbonateNo. Substances146713Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineSecond lineTherapy phaseConsolidationTherapy intentioncurativepalliativeRisksAlopeciaAnemia Hb below 8g/dlCardiotoxicityDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaInfectionsNeuropathyNeutropeniaOral MucositisPyrexiaThromboembolic Event only studiesPublicationAuthorHeld GHorwitz SSieniawski MVan de Wyngaert ZDiseaseEnteropathie assoziiertes T-Zell-Lymphom, Erstlinieperipheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2rezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2rezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3OriginHaematological Sciences, Newcastle University, Newcastle upon Tyne, UKHématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Memorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupProtocols in Revision 8 protocols foundProtocols under revision.BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420 V1.0)CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 40 followed by IVE/MTX - Ifosfamide 3 / Epirubicin 50 / Etoposide 200 / Methotrexate 1500 x 3, Enteropathy-associated T-cell lymphoma, Part A (PID1650 V1.1)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204 V1.0)IVE/MTX - Epirubicin 50 / Etoposide 200 / Ifosfamide 3 / Methotrexate 1500, Enteropathy-associated T-cell Lymphoma, Part B (PID1651 V1.3)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)
